A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians

C Pease; K R Amaratunga; G G Alvarez

doi:10.14745/ccdr.v43i34a02

A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians

Can Commun Dis Rep. 2017 Mar 2;43(3-4):67-71. doi: 10.14745/ccdr.v43i34a02.

Authors

C Pease¹, K R Amaratunga^{2

3}, G G Alvarez^{1

3

4}

Affiliations

¹ Division of Respirology, University of Ottawa, Ottawa, ON.
² Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.
³ Department of Medicine, Division of Infectious Diseases, University of Ottawa, Ottawa, ON.
⁴ Ottawa Hospital Research Institute, Ottawa, ON.

Abstract

Despite recent success in reducing its incidence, tuberculosis remains a considerable challenge in Canada, particularly among foreign-born and Indigenous populations. A key component of the strategy for controlling the disease is the treatment of latent tuberculosis infection. The standard treatment consists of isoniazid (INH) daily for nine months. In recent years, shorter regimens have been developed in the hope of increasing rates of treatment acceptance and completion. Of these, the shortest and most recently developed is a combination of INH and rifapentine taken once weekly for 12 doses (3HP), typically using directly observed therapy (DOT). This regimen has been approved by the Food and Drug Administration in the United States but is not yet authorized in Canada. Based on a rapidly expanding number of observational studies and randomized controlled trials, 12 weeks of 3HP appears to have similar efficacy to nine months of INH, a favourable adverse event profile and potentially improved rates of treatment completion. Although rates of treatment acceptance, the role of self-administered therapy and the regimen's cost-effectiveness within the Canadian context remain uncertain, 3HP is a promising alternative to existing treatments for LTBI.